oral TLR7 agonist RG7854 and HBV core protein allosteric modulator RG7907. Dicerna is retaining an option to co-fund pivotal development of the product globally, which would entitle the company to ...

Median HBV DNA at baseline in these eight patients ... Core promoter, precore and core regions. The core protein was found to be mutated in five of the eight patients in their samples analyzed ...

or HBV core antibody (anti-HBc). The most common cause of HBVr is prolonged immunosuppression due to medications, particularly B-cell depleting agents like rituximab, or disease. HBsAg-positivity ...

Future Virology. 2008;3(3):253-264. HBV budding is driven by the intrinsic property of the S-protein to form particles at the cytoplasmic side of the ER, even in the absence of mature nucleocapsids.